BF Biosciences Limited (PSX:BFBIO)

Pakistan · Delayed Price · Currency is PKR

130.90

-1.72 (-1.30%)

At close: Nov 6, 2026

Market Cap	11.56B -15.2%
Revenue (ttm)	9.81B +42.6%
Net Income	657.49M +33.8%
EPS	7.44 +31.9%
Shares Out	88.33M
PE Ratio	17.60
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,848
Open	132.10
Previous Close	132.62
Day's Range	130.25 - 132.10
52-Week Range	117.20 - 177.99
Beta	-0.11
Analysts	n/a
Price Target	n/a
Est. Earnings	Feb 24, 2027

About BF Biosciences

BF Biosciences Limited, a biotech pharmaceutical company, manufactures, imports, and sells pharmaceutical products in Pakistan, Nepal, Cambodia, Uzbekistan, Kenya, Afghanistan, Mauritania, Switzerland, Sri Lanka, and internationally. The company offers pharmaceutical products for various therapeutic areas, including cardiometabolic, diabetes and anti-obesity, cardiology, urology and nephrology, gastroenterology and liver, anti-fungal, oncology, anti-viral, hepatology, orthopedic, dermatology, and antibiotics. It also provides specialized inject... [Read more]

Industry Pharmaceutical Preparations

Founded 2006

Employees 852

Stock Exchange Pakistan Stock Exchange

Ticker Symbol BFBIO

Full Company Profile

Financial Performance

In fiscal year 2026, BF Biosciences's revenue was 9.46 billion, an increase of 62.08% compared to the previous year's 5.84 billion. Earnings were 632.13 million, an increase of 41.37%.

Financial Statements